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Men who have sex with men (MSM) and transgender women (TGW) are vulnerable 
populations at high risk for HIV infection. Existing HIV prevention methods including 
oral preexposure prophylaxis (PrEP) do not adequately accommodate the diverse 
practices and needs of these vulnerable populations. The overarching theme of the thesis 
is developing PrEP that takes into account the lifestyle and preferences of MSM and 
TGW. Specifically, the thesis responds to the desire by MSM for a medicated lubricant as 
PrEP and the value that TGW place on gender affirming hormone therapy (GAHT) when 
considering PrEP. 
 
Chapter 2 is an open-label study of the colorectal distribution and retention of a rectal gel 
applied with manual dosing as a sexual lubricant compared with applicator dosing. 
SPECT/CT was used to measure distribution and retention 4 hours after application of 
radiolabeled gel. Compared to applicator dosing, manual dosing resulted in delivery of a 
smaller and more variable dose with more variable colonic distribution. 
 
Chapter 3 is a pharmacokinetic study evaluating the effects of GAHT on the plasma and 
tissue concentrations of inactive and active forms of tenofovir (TFV) and emtricitabine 
(FTC) in TGW on GAHT and cisgender men (CGM) not on GAHT. Participants were 
dosed for 7 days with oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) and 
underwent blood and colon sampling for pharmacokinetics. We found that GAHT 





Combined together, the two studies presented in this thesis contribute to the development 
of HIV PrEP that values the desires, preferences and needs of MSM and TGW. Further 
studies are needed to further understand the pharmacokinetics of rectal microbicide gel 
applied as a sexual lubricant and provide greater insight for TGW on the interaction 
between PrEP and GAHT.  
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CHAPTER 1: Introduction 
 
The HIV epidemic continues to have a devastating impact globally. Vulnerable 
populations - men who have sex with men (MSM) and transgender women (TGW) - 
persons who are designated male at birth and identify as women – are at particularly high 
risk of HIV. MSM have a 19 times greater odds of HIV infection compared to the general 
population [1]. TGW are at even higher risk, with 49-fold greater odds of HIV infection 
than all adults of reproductive age [2]. Both MSM and women engage in unprotected 
RAI, which has the highest risk per act of HIV acquisition among sexual behaviors, with 
10 to 20 times greater risk than unprotected vaginal sex [3, 4]. The persistently high 
incidence of HIV in spite of condoms and behavioral strategies presents an urgent need 
for new prevention strategies, such as pre-exposure prophylaxis (PrEP). 
 
1.1 Oral Pre-Exposure Prophylaxis (PrEP) – promises and pitfalls 
Daily oral PrEP with tenofovir (TFV) and emtricitabine (FTC) has provided an exciting 
new approach to HIV prevention. Several studies demonstrate the efficacy of oral 
tenofovir-based regimens in preventing HIV in diverse HIV risk groups [5-10]. Efficacy 
improves substantially – as high as 100% - in research cohorts who sustain a high degree 
of adherence throughout randomized controlled trials [5-10].  
 
Despite the promise of oral PrEP, its efficacy can be crippled by poor adherence in some 
populations, limiting its potential as a singular HIV prevention method [11]. In some 




is problematic, with all randomized controlled trials (RCTs) of oral PrEP, including those 
demonstrating efficacy, depicting waning adherence over time [13-15].  
 
Even in RCTs showing oral PrEP efficacy, low adherence was observed in MSM (iPrEx) 
with only 30% consistently having detectable drug levels [15]. In TGW in iPrEx, 
adherence was even lower at 18% [16]. With study participants incentivized by 
established prior proof of efficacy, subsequent effectiveness studies in MSM and TGW 
(iPERGAY and PROUD) had high adherence [17, 18]. The variable levels of medication 
adherence in these trials are an indirect indication that alternative PrEP dosing 
formulations, among other potential enhancements, are needed to improve adherence to 
PrEP and, therefore, improve PrEP impact. 
 
1.2 HIV microbicides 
 
Looking beyond oral PrEP to other formulations, key lessons can be gleaned from the 
development of HIV vaginal microbicides, which are drugs applied topically to the 
vagina to prevent HIV transmission in women. TFV vaginal gel was found to have 39% 
efficacy (improved to 54% with high adherence) in women in CAPRISA 004 [19]. 
Subsequent studies (VOICE and FACT 001) failed to replicate CAPRISA 004’s efficacy, 
hampered by poor adherence [12, 20]. When asked about reasons for not taking the drug, 
participants cited having difficulty taking a daily regimen, not knowing if the drug works, 
not trusting the product personally and being swayed by concerns from their partners and 
community [21]. While the results were ultimately disappointing, studies of tenofovir 




forefront of HIV prevention drug development. 
 
1.3 Developing HIV prevention products for MSM and TGW 
 
Learning from the failure of TFV vaginal gel in women, a user-centric approach that 
takes into account the social and personal context of product use is critical to maximize 
product use, uptake, adherence and, thereby, efficacy in MSM and TGW. Diverse and 
complex sexual practices drive HIV risk in MSM and TGW, such that multiple 
prevention options are needed to accommodate the behavioral contexts of product use 
[19]. TGW have placed value in having a greater variety of PrEP products [22].  
Furthermore, formulation preference varies among individuals [19], such that having both 
oral and topical PrEP options is likely to more broadly cover the different needs of 
individuals. By analogy, when options for contraception have increased over time, the 
population level of effective contraception rises [23-25].  
 
Rectal microbicides, or rectal products containing drugs for preventing rectal HIV 
transmission through receptive anal intercourse (RAI), are being developed to provide 
another formulation option for HIV PrEP. Some rectal microbicides are designed to be 
behaviorally congruent, meaning that utilization requires little behavioral change from 
typical RAI parasexual practices of using lubricants or douches. Lubricants are frequently 
used among MSM with 45-77% reporting use with RAI [97-99] with the exception of one 
study citing a low frequency of 17.4% [100]. Furthermore, MSM have expressed desire 
for a medicated lube for HIV prevention. Similarly, rectal douches are used frequently 




[26-31]. In one survey of MSM, 98% were highly likely to use a rectal microbicide 
douche [32]. Substituting non-medicated with medicated lubricants or douches does not 
require changing behavior, only product selection. As rectal microbicides integrate 
microbicide delivery into typical sexual practices, they may be more acceptable and 
promote better adherence than daily oral PrEP.  
 
In addition to broadening the menu of formulation options for HIV prevention, 
understanding the factors that limit or promote uptake and use of HIV PrEP in different 
populations, such as TGW, is important for enhancing adherence. HIV PrEP development 
in TGW should recognize the unique social and personal circumstances that make 
adherence to PrEP challenging. Most TGW use gender-affirming hormone treatment 
(GAHT), including estrogen, to induce feminization which they often prioritize over 
PrEP [33]. Among TGW, 86.6% are unwilling to use PrEP due to worries that their 
hormone regimens may be affected by PrEP [34]. Focus groups with TGW have 
indicated additional barriers to PrEP uptake and use including pill burden, concerns about 
side effects, and a dearth of PrEP research focused on TGW. Facilitators to PrEP use 
include having more research on PrEP in TGW, who have been underrepresented in PrEP 
trials. Bridging the barriers limiting uptake and use of PrEP in TGW will be a necessary 
part of successful PrEP development in TGW. 
 
1.4 Chapters 2 and 3 
 
The overarching goal of this thesis is to develop HIV prevention products that are 




HIV PrEP development that takes into account the social and personal context of product 
use will be critical to maximize product use, uptake and efficacy in these high-risk 
groups.  
 
Chapter 2 addresses the desire by MSM for a rectal microbicide that can be used as a 
sexual lubricant, without the use of an applicator. Specifically, the study asks the question 
of whether using medicated lubricant, in the typical way a sexual lubricant used, will 
provide adequate colorectal distribution in sufficient amount to provide rectal HIV 
prevention.  
 
Chapter 3 aims to address the barriers limiting PrEP uptake and use in TGW by providing 
TGW-focused research and pharmacokinetic support that daily oral PrEP is likely 
efficacious in TGW. Chapter 3 is a pharmacokinetic (PK) study of oral Tenofovir-
Emtricitabine in TGW on feminizing hormone therapy.  
 
Drug development in HIV prevention cannot occur in isolation and must value the end-
user’s preferences and lifestyle. By taking into account the end user’s preferences, 
lifestyle and concerns, the studies in this thesis utilize a user-centric approach to 
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Given the rising HIV incidence in men who have sex with men (MSM) despite repeatedly 
proven effectiveness of oral HIV pre-exposure prophylaxis, behaviorally congruent 
periodic dosing strategies, such as dosing microbicides as lubricants, are now in demand. 
Rectal microbicide gel studies largely administer gels using vaginal applicators, which 
have not been well received and do not mimic lubricant use.  
 
2.12 Methods 
We compared rectal gel manually dosed as lubricant with applicator dosing in five 
healthy, HIV-negative MSM who received 10 or 3.5 ml of 99mTc-DTPA-radiolabeled 
hydroxyethyl cellulose universal placebo gel intrarectally. After washout, participants 
received 10 ml of radiolabeled Wet® Original® lubricant to apply to the anus with fingers 
and/or a phallus in a manner typical of sexual lubricant use with a partner, followed by 
simulated receptive anal intercourse. Single-photon emission computed tomography with 
transmission computed tomography was performed 4 h after each gel administration.  
 
2.13 Results 
Manual dosing was associated with more variable rectosigmoid distribution, 4.4–15.3 cm 
from the anorectal junction, compared with more uniform distribution, 5.9–7.4 and 5.3–
7.6 cm after 10 and 3.5 ml applicator dosing, respectively. A significantly smaller fraction 
of the initial 10 ml dose was retained within the colon after manual dosing, 3.4%, 




(both p < .001).  
 
2.14 Conclusion 
Manual dosing of a sexual lubricant delivered a small, variable fraction of the dose with 
variable rectosigmoid distribution compared with applicator dosing. These results raise 
concern that dosing a rectal microbicide gel as a sexual lubricant may not provide 






The rising incidence of HIV infection in men who have sex with men (MSM) in many 
regions highlights the need for pre-exposure prophylaxis (PrEP). Recognizing that 
effectiveness of oral PrEP hinges on high levels of adherence and that MSM practicing 
receptive anal intercourse (RAI) already commonly use sexual lubricants [35], 
behaviorally-congruent PrEP in the form of anal lubricant is of great interest.  
 
Studies of rectal microbicide gels largely employ vaginal applicators that neither align 
with RAI practices [36] nor mimic real-world lubricant use [37]. Trial participants voice 
concerns about applicator comfort, size, transportability, and visual appeal, potentially 
limiting acceptability and future adherence [36, 38, 39]. Participants and advocates desire 
a microbicide gel that can be applied as anal lubricant without an applicator.  
 
Rectal microbicide surrogates dosed with an applicator reach colorectal distributions 
overlapping that of HIV surrogates and achieve excellent retention [40]. To assess 
whether similar distribution and retention occur when rectal gels are applied as sexual 
lubricants without applicators, we performed an open-label cross-over study comparing 
colorectal distribution, percentage dose retained, and volume retained, among manual and 







This study was approved by the Johns Hopkins Medicine Institutional Review Board. 
Participants provided informed consent before screening. Eligible participants were 
healthy, HIV-seronegative MSM who had participated in a sequence-randomized cross-
over study of a 10 and 3.5 mL hydroxyethyl cellulose (HEC) universal placebo gel 
administered intrarectally by a study investigator utilizing a 4 cm plastic 
applicator attached to a syringe [41].  
 
We enrolled five participants from the prior study to evaluate manual dosing of gel as an 
anal lubricant without an applicator. The lubricant gel, Wet® Original®, is sold over-the-
counter and is an aqueous gel like HEC. Wet® Original® was selected based on brand 
popularity in an International Rectal Microbicide Advocates survey (M. LeBlanc, 
Personal Communication, September 21, 2015).   
 
2.3.2 Study Design 
Participants received a 10 mL lubricant pillow, which is a plastic pouch filled with gel, 
radiolabeled with 1,000 µCi of 99mTc (technetium)-DTPA (diethylenetriamine 
pentaacetate). Participants were asked to apply the gel as they would apply anal lubricant 
with a sexual partner, using a phallic device as a surrogate for a penis. This was followed 
by simulated unprotected RAI (suRAI), gamma emission measurements of study 
materials, and radiolabeled gel imaging with single-photon emission computed 
tomography with transmission computed tomography (SPECT/CT) 4 hours after dosing, 





2.3.3 SPECT/CT Imaging and Analysis 
Colon SPECT data was fit using a three-dimensional curve-fitting algorithm.  Colorectal 
distribution parameters, Dmax and Dmin (maximal and minimal colorectal distances of 
radiosignal), DCmax (distance associated with maximum concentration), and Dave (mean 
resident distance) were determined as previously described [43].  
 
Region of interest (ROI) analysis of SPECT/CT images utilized previously described 
software [42]. For each axial slice on attenuation-corrected SPECT scans, ROIs were 
drawn around areas of signal intensity to quantify differences between intraluminal and 
extracorporeal signal. ROIs proximal to the anorectal junction, approximated as the axial 
CT slice inferior to air visualization within the rectal ampulla, were labeled intraluminal. 
For manual dosing, percentage dose retained was estimated as the product of three 
variables: percentage of gel removed from the pillow, percentage of removed gel applied 
to the body, and percentage of applied gel that was intraluminal. Percentage removed, 
applied, and intraluminal were determined by weights, dosimetry, and ROIs, respectively.   
 
For applicator dosing, percentage dose retained was estimated as previously described 
[41]. Volume retained was estimated as the product of percentage dose retained and 
volume of the original dose unit. Continuous measures were described as medians and 
ranges. Differences among dosing arms were tested with Friedman repeated measures 
analysis of variance (ANOVA), followed by Tukey’s test for multiple comparisons, with 






Five healthy HIV-negative MSM were enrolled. Median age was 48 years (23-57). For 
manual dosing, four participants used fingers and phallus to administer lubricant, while 
one used only the phallus. Similar colorectal distribution was observed among dosing 
arms, with no statistically significant differences in Dmax, DCmax or Dave (Figure 2.2). Dmin 
was 2.8 and 3.2 cm greater for manual than 10 and 3.5 mL applicator dosing, respectively 
(p=0.01, p<0.01) (Figure 2.2). Dmax was more variable for manual than 10 and 3.5 mL 
applicator dosing, with ranges of 4.4–15.3, 5.9–7.4, and 5.3–7.6, respectively.  
 
For manual dosing, participants removed a median of 3.2 mL (1.8, 6.6) from the 10 mL 
pillow (32%). Then 20.8% (17.1, 39.9) of removed lubricant was applied to the body, and 
51% (20, 89) of applied lubricant was intraluminal based on imaging (Figure 2.3 and 
Figure 2.4). Thus, of the initial 10 mL dose contained in the pillow, 3.4% (0.01, 23.4) 
was delivered intraluminally.   
 
For applicator dosing, 94.9% (94.3, 95.6) and 88.4% (86.4, 89.5) of the 10 and 3.5 mL 
dose contained in the syringe were ejected, respectively. For both arms, 100% (100, 100) 
of ejected gel was delivered intraluminally. Thus, of the 10 and 3.5 mL doses contained 
in the syringe, 94.9% (94.3, 95.6) and 88.4% (86.4, 89.5) of the full original dose, 
respectively, were delivered intraluminally. Overall, percentage dose retained for manual 
dosing was 32-fold and 29-fold less than 10 and 3.5 mL applicator dosing, respectively 
(both p<0.001). The median intracolonic volume delivered was 0.3, 9.5 and 3.1 mL for 





The number of participants was too small to statistically test for participant variables, like 
age, which might correlate with measured parameters. However, the participant with the 
greatest percentage of retained gel and the greatest luminal distribution after manual 




We describe the first study evaluating distribution and retention of a rectal gel 
administered as a sexual lubricant. Compared to applicator dosing, manual dosing 
delivered a small, variable dose with variable rectosigmoid distribution. Although highly 
variable, similar median colorectal distribution estimates of the manually applied gel, 
when compared with the applicator applied gel, were unanticipated in light of the far 
smaller percentage of dose retained with manual dosing. This distribution similarity may 
be explained by the gel vehicles having different osmolalities (3,679 and 304 mOsm/kg 
for Wet® Original® and HEC gels, respectively). The lubricant, with 10-fold greater 
osmolality due largely to the glycerin content (Table 2.1), likely drew additional fluid 
intraluminally, increasing volume and colonic spread. For manual dosing, the larger Dmin 
was likely related to the radiosignal being below the limit of quantitation because of the 
small dose retained in the rectum. Although high osmolality gel may provide the better 
option for increased luminal distribution, it is also associated with significant epithelial 





The highly variable rectosigmoid distribution of lubricant among participants could be 
attributed to diverse dosing practices, resulting in heterogeneous application methods and 
dosing volumes. For example, the finger-free dosing method of one participant achieved 
nearly a 10-fold greater amount of retained lubricant within the colorectal lumen. 
However, adapting new methods of gel dosing might also introduce a requirement for 
behavioral change and our intent was to see how well manual gel dosing fared with 
existing behaviors. 
 
The study had several limitations including a small sample size. suRAI only occurred 
with manual dosing; however, based on CHARM-02, suRAI is unlikely to alter colorectal 
distribution or retention [42]. Investigators administered the gel volume using a 
syringe/applicator, whereas participants performed manual dosing,  removing as much 
gel from the pillow as needed for lubrication based on personal preference; this 
contributed to the greater efficiency of applicator dosing. In addition, HEC gel and a 
lubricant were used, rather than a rectal microbicide gel in development, so no 
information could be gleaned about the distribution of an active pharmaceutical 
ingredient. Finally, manual dosing was performed with a restricted maximum gel volume 
without a sexual partner, diverging from real-world lubricant practices. 
 
This study suggests that, without applicators, manual dosing of a rectal microbicide gel as 
lubricant may not provide adequate or predictable mucosal coverage, with possible 
negative impact on HIV protection. A critically complementary study, MTN-033/IPM-




concentration and ex vivo antiviral effect in a larger population. Ultimately, manual 
dosing of rectal microbicide gel as lubricant may require modifying microbicide 
formulations in development to achieve adequate antiretroviral delivery. Should rectal 
gels require applicators to reach HIV-protective colorectal distribution, wide acceptance 
may be challenging. 
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Table 2.1. Ingredients of gels used for Applicator and Manual Dosing 
 
Dosing Method Applicator Manual 

























Figure 2.2. Colorectal distance parameters for manual and applicator dosing 
 
 
Dmax is the maximal colorectal distance of the radiosignal. Dmin is the minimal colorectal 
distance of radiosignal. DCmax is the distance associated with maximum concentration. 
Dave is the mean resident distance. Each symbol represents one participant.  







Figure 2.3. Distribution of radiolabeled gel within and outside the colon for manual 
and applicator dosing. 
 
 
Manual dosing images (top panels) indicate a substantial fraction of the dose falling 
outside the body (extracorporeal), posteroinferior to the pelvis, mostly in the midline 
gluteal folds in addition to a fraction within the colonic lumen. The intrarectal dosing 
images (bottom panels) indicate all visible signals within the colonic lumen within the 
pelvis. Fused SPECT and CT images (left panels) indicate bone in amber scale with 
lumbosacral spine, pelvis, and humerus (top to bottom); color in images indicate 
radiolabel intensity. Right panels are maximum intensity projections of SPECT image 
(color scale signal intensity) at similar angle of rotation without bony landmarks; labels 
indicate intraluminal and extracorporeal radiolabel. SPECT, single-photon emission 





Figure 2.4. Percentage of dose retained and volume delivered of manual and 
applicator dosing. 
 
*Friedman repeated measures ANOVA; Tukey test for multiple comparisons p<0.05; n.s. 
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3.1 Abstract  
 
3.11 Introduction.  
Oral HIV Pre-Exposure Prophylaxis (PrEP) with tenofovir (TFV) disoproxil fumarate 
(TDF)/emtricitabine (FTC) is highly effective. Transgender women (TGW) have 
increased HIV risk, but have been underrepresented in trials. For TGW on estrogens for 
gender-affirming hormone treatment (GAHT), TDF/FTC-estrogen interactions may 
negatively affect HIV prevention or gender-affirming goals. Our aim was to evaluate any 
pharmacokinetic drug-drug interaction between GAHT and TDF/FTC. 
 
3.12 Methods.  
We performed a pharmacokinetic study, in an urban outpatient setting in 2016-2018, of 
the effects of GAHT on TFV, FTC and the active forms TFV diphosphate (TFV-DP) and 
FTC triphosphate (FTC-TP) in eight TGW and eight cisgender men (CGM). At 
screening, participants were HIV negative. TGW were to maintain their GAHT regimens 
and have plasma estradiol concentrations >100 pg/mL. Under direct observation, 
participants took oral TDF/FTC daily for seven days. At the last dose, blood was 
collected pre-dose, 1, 2, 4, 6, 8 and 24 hours, and colon biopsies were collected at 24 
hours to measure drug concentration. TGW vs. CGM concentration comparisons used 
non-parametric tests. Blood and colon tissue were also obtained to assess kinase 
expression. 
 




Plasma TFV and FTC C24 (trough) concentrations in TGW were lower by 32% (p=0.010) 
and 32% (p=0.038), respectively, when compared to CGM. Plasma FTC 24-hr area under 
the concentration-time curve in TGW was significantly lower by 24% (p=0.028). Plasma 
TFV 24-hr area under the concentration-time curve, plasma TFV and FTC 
concentrations, as well as all other pharmacokinetic measures, were not statistically 
significant when comparing TGW to CGM. Estradiol concentrations were not different 
comparing before and after TDF/FTC dosing. Plasma estrogen concentration, renal 
function (estimated creatinine clearance and glomerular filtration rate), and TFV and FTC 
plasma concentrations (trough and area under the concentration-time curve) were all 
correlated. 
 
3.14 Conclusion.  
GAHT modestly reduces both TFV and FTC plasma concentrations. In TGW taking 
GAHT, it is unknown if this reduction will impact the HIV protective efficacy of a daily 
PrEP regimen. However, the combination of an on demand (2+1+1) PrEP regimen and 






Transgender women (TGW) are at high risk for HIV transmission with a worldwide 
prevalence of 19% [2], making them a critical population for HIV prevention with pre-
exposure prophylaxis (PrEP). While PrEP willingness in TGW is high [45, 46], several 
challenges limit PrEP use and efficacy. Barriers to PrEP uptake in TGW include concerns 
about side effects and the effect of PrEP drugs on gender-affirming hormone treatment 
(GAHT), limited transgender-inclusive PrEP promotion, and medical mistrust [47]. The 
iPrEx trial of oral daily tenofovir disoproxil fumarate (TDF) 300 mg/emtricitabine (FTC) 
200 mg (TruvadaTM Gilead Sciences, Inc. Foster City, CA) showed efficacy in men who 
have sex with men (MSM) and TGW, collectively [48]. However, a subgroup analysis of 
TGW on GAHT showed lower PrEP efficacy and lower adherence (as measured by 
pharmacologic assessment) when compared to MSM and TGW not on GAHT; also, the 
pharmacologically-based adherence benchmarks used were established in persons not on 
GAHT [16]. Most TGW use GAHT, including estrogen, to induce feminization [49]. In 
one survey, 86.6% of TGW cited unwillingness to use PrEP due to worries that their 
hormone regimens may be affected [50]. Surgical interventions for both hormonal 
modification (e.g., orchiectomy) and anatomic modification ranging from silicone 
injections to gender reassignment surgery are also elected, though with less frequency.   
 
The impact of GAHT on TDF/FTC metabolism is poorly understood. The activation of 
tenofovir (TFV) and emtricitabine (FTC) requires intracellular phosphorylation by 
different nucleotide kinases in different tissues. In cell culture, estrogen increases the 




female genital tract CD4+ cells show decreased TFV-diphosphate (TFV-DP) 
concentrations in the presence of progesterone and estradiol [52]. Ex vivo, estrogen 
increases cytosolic 5’-nucleotidase activity in only some human cervicovaginal cell 
types, but there are no data in colorectal cells [10]. In vitro, the uptake of TFV and FTC 
into cervicovaginal cell lines increases or decreases varying with timing of estrogen 
addition and cell type [53]. Clinically, pregnancy is associated with high levels of 
endogenous estrogen compared to the non-pregnant state and changes in renal physiology 
significantly increase the clearance of many renally cleared drugs. The complex 
relationship between hormones and TDF/FTC uptake, activation, and clearance make it 
challenging to predict the pharmacokinetic (PK) interaction between GAHT and 
TDF/FTC.  
 
The aim of the study was to investigate whether drug in blood plasma, peripheral blood 
mononuclear cells (PBMCs), and colon tissue, following daily oral TDF/FTC dosing 




This was a phase one open-label PK interaction study of oral TDF/FTC and GAHT in 
TGW and CGM. The study was conducted in an urban outpatient setting in Baltimore, 
Maryland, from April 2016-April 2018, after approval by the Johns Hopkins Medicine 
Institutional Review Board. The primary objective was to compare steady-state plasma, 




and FTC-TP concentrations in TGW on estrogen and CGM not on estrogen. Other 
objectives included assessing the effect of exogenous estrogen on both nucleotide kinase 
expression of enzymes relevant for intracellular phosphorylation of TFV and FTC and 
colon tissue HIV infectivity assessed by ex vivo HIV challenge of colon tissue explants.  
 
3.32 Study Participants  
Eligible participants were healthy HIV-seronegative self-identified TGW and CGM aged 
18 to 65 years recruited from Baltimore, Maryland. TGW had to be taking estrogen and 
have a serum total estradiol concentration >100 pg/mL indicating consistent estradiol use. 
The estrogen formulation, dose, route, and frequency were not otherwise restricted; other 
GAHT medications could be taken. Exclusion criteria included enrollment in HIV 
clinical trials, colorectal symptoms, rectal infection, hepatitis B surface antigen (HBsAg), 
altered gastrointestinal anatomy, and concomitant medications with potential for toxicity 
or interactions.  
 
3.33 Study Procedures 
After informed consent, participants were screened with history, physical, and laboratory 
evaluation for hematology, chemistries, HBsAg, HIV, and syphilis; TGW had serum 
estradiol measurements. Eligible participants underwent daily directly observed dosing of 
oral TDF/FTC in the research clinic each morning from Day 0 to Day 7 to assure TFV-
DP and FTC-TP reached steady state [54]. Due to varied GAHT regimens, the only 
GAHT dose managed by the study team was on Day 7 when the dose was held until after 




dose, 1, 2, 4, 6, 8 and 24 hours (C24) post-dose. PBMCs were collected pre-dose, 2, 8, and 
24 hours post-dose for TFV-DP, FTC-TP, and kinase expression. Serum hormones were 
collected 24 hrs after the final TDF/FTC dose (Day 7, C24). Flexible sigmoidoscopy with 
30 rectosigmoid biopsies was performed approximately 24-26 hours after the final 
TDF/FTC dose for histology, PK, kinase expression, and ex vivo explant challenge. 
 
3.34 Histology 
Histology was pathologist scored for surface denudation (0-3 scale indicating thirds of 
epithelial surface affected), lamina propria hemorrhage (0-3 scale indicating thirds of 
lamina propria affected), and number of apoptotic bodies per 20x field as previously 
described [55].  
 
3.35 Pharmacokinetic Sample Processing 
For blood processing in all participants, plasma was prepared by centrifugation of 
coagulated blood in serum separator tubes at 1,500 × g for 10 min at 4°C, aliquoted into 
cryovials, and stored at −80°C until analysis. PBMCs were isolated via centrifugation of 
a cell preparation tube (CPT) at 1,800 × g for 20 min at 20–25°C, washed once with 
phosphate-buffered saline (PBS), and centrifuged at 400 × g for 15 min at 4°C. Cells were 
resuspended in 10 ml PBS for cell counting. Cells were centrifuged again at 400 × g for 
15 min at 4°C. Cell pellets were lysed with 2 mL of 70% ice cold methanol in water and 





Colon biopsies were collected via flexible sigmoidoscopy 10–20 cm from the anus using 
3.7-mm pinch biopsy forceps (Microvasive no. 1599; Boston Scientific Corp., Natick, 
MA). Biopsies were placed in RPMI medium with L-glutamine and 10% fetal bovine 
serum (R10 media) until processing. Biopsies for drug concentration were weighed and 
stored at -80˚C prior to analysis. To release colon tissue cells for intracellular drug 
analysis, biopsies were incubated with an enzyme cocktail (collagenase type II, DNase I) 
in RPMI containing L-glutamine, HEPES, and 10% fetal bovine serum (FBS) using the 
37C_h_TDK3 tumor dissociation program on a GentleMACS (Miltenyi) tissue 
dissociator [56]. Cells were counted via the Guava/Millipore EasyCyte Plus (Millipore, 
Billerica, MA). Thereafter, cells were processed similarly to the PBMCs. 
 
3.36 Hormone Sample Processing and Analysis 
Serum for hormone analysis was per protocol of Brigham Research Assay Core (BRAC; 
Brigham and Women’s hospital, Boston, MA), which performed the assays, including 
LC-MS for total estradiol and total testosterone, tracer equilibrium dialysis for free 
testosterone, and immunoassay for LH and FSH. 
 
3.37 Drug Concentration Analysis 
TFV, FTC, TFV-DP, and FTC-TP concentrations were determined by previously 
described liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) methods 
validated for biological matrix by the Clinical Pharmacology Analytical Laboratory 
(CPAL) [56-58]. CPAL participates in the National Institutes of Health-supported 




approval and periodic proficiency testing [18]. Assays were validated based on the Food 
and Drug Administration Guidance for Industry, Bioanalytical Method Validation and 
met all acceptability criteria. Assay lower limits of quantification (LLOQ) were: plasma 
TFV and FTC, 0.31 ng/mL; tissue TFV, 0.05 ng/sample (median LLOQ based on biopsy 
weights, 0.002 ng/mg); tissue FTC, 0.25 ng/sample (median LLOQ based on biopsy 
weights, 0.010 ng/mg); PBMC and tissue TFV-DP, 5 fmol/sample; PBMC and tissue 
FTC-TP, 50 fmol/sample.  Intracellular metabolite concentrations were normalized to cell 
counts and tissue weights and reported as fmol/106 cells and fmol/mg, respectively. 
Median LLOQ values for TFV-DP and FTC-TP concentrations in PBMCs, colonic tissue 
cells, and tissue homogenates were 0.446 fmol/106, 0.721 fmol/106, and 0.208 fmol/mg 
and 4.46 fmol/106, 7.21 fmol/106, and 2.08 fmol/mg, respectively.  
 
3.38 Kinase Expression 
Tissues samples and PBMCs were lysed using 1mM phenylmethylsulfonyl fluoride 
(PMSF) and protease/phosphatase inhibitor cocktail (Cell Signaling Technology).  Lysate 
was centrifuged at 6000 × g for 10 min at 4°C and supernatant was collected for protein 
determination using a BCA protein assay kit (ThermoFisher). A 50 µg protein sample 
was resolved by SDS gel electrophoresis and transferred to a nitrocellulose membrane.  
Membranes were probed using primary antibodies for adenylate kinase 2 (AK2), creatine 
kinase muscle (CKM), pyruvate kinase liver and red blood cell (PKLR), pyruvate kinase 
muscle (PKM) (all kinase antibodies from Fisher Scientific), GAPDH (Cell Signaling), or 
β-actin (Cell Signaling). Visualization was performed using SuperSignal West Dura or 





3.39 Ex vivo Colon Tissue Explant HIV Challenge 
Four colon biopsies were incubated for 2hr each with 103 TCID50 per mL of HIV-1, strain 
Ba-L from Advanced Biotechnologies, Inc. (Columbia, MD) in a 24-well plate after 
which they were placed in four individual wells on Surgifoam rafts (Ethicon Endo-
Surgery, Inc., Somerville, NJ) in culture media for 15 days. On days 4, 7, 10, and 14, all 
culture media were harvested and replaced (except final day 14) with fresh media. 
Harvested media were assayed for HIV-1 p24 antigen using the Alliance HIV-1 ELISA 
kit (PerkinElmer, Waltham, MA) according to manufacturer. Cumulative p24 antigen 
produced in supernatant over the incubation period was divided by biopsy weight for 
weight-adjusted cumulative p24 antigen. Median (of four) biopsy weight-adjusted 
cumulative p24 produced over 14 days was the unit of analysis [19].  
 
3.40 Pharmacokinetic and Statistical Analysis 
PK parameters in plasma and PBMC (area under the concentration versus time curve 
from zero to 24 hours [AUC0-24], peak concentration [Cmax], trough concentration [C24], 
steady-state total clearance [CLss/F], and volume of distribution based on the terminal 
phase [Vz/F]) and colon tissue concentration 24-hours post-dose (C24) were estimated 
using non-compartmental analysis (Pharsight WinNonlin v. 8.1, Certara, Inc., Cary, NC) 
and summarized using median and interquartile range (IQR). Differences between gender 
groups were compared using non-parametric Wilcoxon rank sum test; correlations 
between variables were assessed using Spearman rank correlation test (IBM SPSS, v. 




sample size enabled detection of a 1.4 effect size with 80% power and 5% two-sided 
alpha error.   
 
3.4 Results 
3.41 Demographics and Clinical characteristics 
Eight TGW and eight CGM were enrolled. Three-quarters of participants in both 
categories were of African ancestry. TGW had 35% higher BMI than the CGM (p=0.061; 
Table 3.1), but the effect was not statistically significant. TGW self-reported GAHT 
regimens varied widely, and GAHT use ranged in duration from 1 to 27 years (Table 
3.2). Six (75%) TGW were taking spironolactone in combination with various estrogen 
regimens. At screening, median (IQR) plasma estradiol concentrations were 756 (187 – 
1,370) pg/dL. No participants had previously elected gender-affirming surgical 
interventions.  
 
3.42 PrEP PK 
Concentration-time profiles of plasma TFV and FTC (Figure 3.1) indicate biphasic 
decline after peak concentration with TGW median concentrations for both drugs falling 
below the concentrations for CGM at all times and progressively so after peak 
concentrations are achieved. PBMC TFV-DP concentrations are nearly flat, and FTC-TP 
concentrations show more gently rounded peak concentrations compared to plasma FTC 





Plasma TFV trough concentrations (C24) in TGW were lower by 32% (p=0.010) when 
compared to CGM. AUC0-24 was 27% lower (p=0.065) and clearance (CLss/F) was 38% 
higher (p=0.065) in TGW compared to CGM (Table 3.3). Plasma TFV Cmax and V/F 
were not different between gender cohorts. In TGW, plasma FTC trough (C24) and AUC0-
24 were lower by 32% (p=0.038) and 24% (p=0.028), respectively, while CLss/F was 
higher by 31% (p=0.028) when compared to CGM; V/F was higher in TGW by 26% 
(p=0.065) when compared to CGM (Table 3.4), but the effect was not statistically 
significant. FTC Cmax was not different between gender cohorts. There were no 
statistically significant PK differences between TGW and CGM in PBMC or colon tissue 
for any analytes. 
 
3.43 Kinase Expression 
Expression of adenylate kinase 2 (AK2), pyruvate kinase muscle (PKM) and pyruvate 
kinase liver and red blood cell (PKLR) in PBMC did not differ over time at 0, 2, 8 and 24 
hours between CGM and TGW (Figure 3.2).  Expression of creatine kinase muscle 
(CKM) and AK2 in colon tissue did not differ between CGM and TGW (Figure 3.2).  
 
3.44 Pharmacodynamics 
There were no significant differences in median (IQR) cumulative p24 produced by 
colorectal tissue explants between TGW and CGM (9.3 [8.1-13.6] vs 6.8 [5.5-13.3] 
pg/mg tissue, p=0.366). 
  




After seven days of TDF/FTC dosing (Day 7), concentrations for all measured hormones 
were unchanged compared to baseline (all p values > 0.15) (Table 3.5). However, the 
heterogeneity in GAHT regimens and the absence of directly observed GAHT dosing 
meant hormone sampling before and after the TDF/FTC dosing period may not have been 
at steady state. After seven days of TDF/FTC dosing, estradiol concentrations were 25-
fold higher in TGW compared to CGM. FSH, LH, total and free testosterone in CGM 
ranged from 2% to 8% of the concentrations measured in TGW after seven days of 
TDF/FTC dosing (all p values < 0.05).  
 
3.46 Correlation between PrEP PK parameters and Hormones 
Estradiol dose and plasma FTC AUC0-24 (r=-0.68, p=0.007) were strongly negatively 
correlated. Plasma TFV trough concentrations were negatively correlated with both 
estradiol dose (r=-0.53, p=0.04) and Premarin dose (r = -0.54, p=0.03). Correlation 
between GAHT doses and all other PK parameters were not statistically significant. 
Serum estradiol concentrations were moderately correlated with plasma C24 
concentrations of TFV (r = -0.54, p=0.03) and FTC (r = -0.52, p=0.04). FSH 
measurements were moderately correlated with plasma C24 FTC concentrations (r=0.61, 
p=0.02) and PBMC TFV-DP Cmax (r = 0.58, p=0.02). Other hormone and TDF/FTC PK 
parameters were not statistically significantly correlated.  
 
3.47 Renal function 
Renal function in TGW was significantly higher when compared to CGM using all three 




glomerular filtration rate (GFR) estimated using both MDRD and CKD-EPI equations 
(all p<0.01) (Table 3.6). When we substituted the female term for the male term in the 
two GFR estimating equations for TGW on GAHT, the differences between TGW and 
CGM largely disappeared and were no longer statistically different. Estimated CrCl 
remains significantly higher for TGW compared to CGM when substituting female for 
male for TGW. Plasma TFV and FTC trough concentrations (C24) and exposure (AUC0-
24) were all strongly negatively correlated with all three measures of renal function (r 
range -0.65 to -0.82, p values < 0.02 in all comparisons). When the formulas for females 
were substituted for TGW, the correlation dropped slightly. 
 
3.48 Histology 
Surface denudation, lamina propria hemorrhage, and apoptotic bodies scores did not 
differ between TGW and CGM. 
 
3.5 Discussion 
We found a 24-32% reduction in plasma TFV and FTC AUC0-24 and C24 in TGW on a 
variety of estrogen regimens when compared to CGM.  The iFACT study also showed a 
reduction in plasma TFV – 18% C24 and 12% AUC0-24 – in 20 TGW on a standardized 
estrogen/cyproterone regimen [20]. The different magnitude of TFV reductions may have 
been due to study differences, e.g., higher estrogen doses in some of our participants, 
different anti-androgens, and use of parallel group design in our study. Another PrEP-
GAHT interaction study found a 7-fold reduction in rectal tissue homogenate TFV-




this regard, our active phosphorylated TFV and FTC analytes were not statistically 
significant. However, our assessment of these intracellular readouts are limited by greater 
assay variability, small sample size, and sparse sampling. In addition, detailed 
examination of the plasma ARV and hormone concentrations indicate GAHT non-
adherence in some participants possibly related to a drug-drug interaction not at steady-
state, which would result in a delayed impact on the relatively longer half-life of the 
phosphorylated drug analytes when compared to parent drug in plasma. 
 
The magnitude of reduced plasma TFV and FTC exposure associated with GAHT 
regimens in these studies is consistent with taking only five doses (Hopkins) or six doses 
(iFACT) per week when compared to taking 7 daily TDF/FTC doses each week, based on 
HPTN 066 directly observed TDF/FTC dosing [54]. In HPTN 066, which reported 
combined results for CGM and cisgender women not on GAHT, the median (IQR) 
steady-state TFV and FTC serum concentrations were 52 ng/mL (49-56) and 71 ng/mL 
(68-82), respectively [12]. The iPrEx study demonstrated highly effective oral TDF/FTC 
as PrEP with only four doses per week, motivating the Ipergay and Prevenir on demand 
2+1+1 TDF/FTC regimens, which demonstrated very high 86% and 100% HIV 
protection, respectively, in MSM and TGW [59, 60]. However, there were too few TGW 
in those studies to draw conclusions regarding PrEP effectiveness on GAHT. 
Theoretically, one would expect the combination of reduced concentrations from both the 
2-1-1 regimen and GAHT to result in a dose frequency equivalent of two to three doses 
per week. At this dose frequency, PrEP efficacy in the iPrEx models would predict 




2-1-1 regimen in TGW on GAHT, at least until more rigorous PK studies address optimal 
PrEP dosing in TGW.   
 
The mechanism behind lower plasma TFV and FTC in the setting of exogenous estrogen 
(and many also with spironolactone) is not clear. The TFV plasma clearance (CLss/F) 
was higher in TGW, though the effect size was not statistically significant, without 
parallel difference in volume of distribution (Vz/F). Because clearance and volume are 
influenced by oral bioavailability when dosing is oral, the difference in clearance and 
volume changes suggests bioavailability was not a major factor. For FTC, both clearance 
and volume changed similarly (with small differences in magnitude and statistical 
significance). Therefore, bioavailability or volume may differ between cohorts. However, 
we have no explanation for this and find more consistent evidence for a difference in 
clearance. TGW had markedly higher creatinine clearance and eGFR when compared to 
CGM participants, which might account for the major mechanism for reduced 
concentrations of TFV and FTC, both of which are primarily eliminated through renal 
clearance. We also observed a correlation of serum estrogen concentration with both TFV 
and FTC reduction and renal glomerular function increase.  We found that estradiol does 
not affect the kinases that phosphorylate TFV in plasma and colon tissue, but this might 
have been the result of off-setting decreases in plasma parent drug PK and increases in 
kinase effects (predicted by in vitro data) [9].    
 
Whether this difference in renal function is due to estradiol or simply an association is 




estrogens and decreasing renal function with chronic estrogen dosing [62, 63]. A more 
mechanistic explanation may involve the estrogen effect in upregulation of angiotensin-2 
receptor (AT2R) expression resulting in vasodilation and increased clearances shown in 
rodents, though supraphysiologic estrogen concentrations result in vasoconstriction [64-
68]. In addition, testosterone downregulates AT2R expression, resulting in decreased 
vasodilation [69]. Since testosterone concentrations are reduced by a variety of drugs 
used in GAHT regimens, resulting in greater than 20-fold lower free testosterone in our 
TGW compared to CGM participants, this may be an additional mechanism of enhanced 
renal clearance of TFV and FTC. We did not assess angiotensin receptor expression to 
explore this potential explanation. 
 
While we did not identify an impact of PrEP drug on estrogen concentrations, the 
heterogeneity of estrogen formulations and doses among the GAHT prevented us from 
sampling plasma to assess estrogen concentrations reliably at times coinciding with 
pseudo steady-state conditions. In addition, we did not use directly observed dosing of all 
GAHT drugs (unlike with TDF/FTC dosing). As a result, we are not highly confident 
about the finding of no TDF/FTC impact on estrogen concentrations. In contrast, the 
iFACT study team was able to employ a standardized GAHT regimen of estradiol and 
cyproterone acetate and demonstrated that TDF/FTC dosing did not affect estrogen 
concentration. Further, since GAHT regimens are often adjusted to achieve desired 
subjective and objective effects in clinical practice, even modest TDF/FTC impacts on 





Our study also suggests caution when using pharmacologically-based adherence 
benchmarks established in one population when applied to another. In iPrEx, some of the 
concentration difference noted in TGW on GAHT may be attributable to GAHT-PrEP 
interactions in addition to adherence. A clearer example of adherence mischaracterization 
would be in pregnant women in whom plasma TFV concentrations are 58% lower than in 
non-pregnant women when controlling for adherence [33].  
 
3.6 Conclusions 
 We demonstrated that GAHT regimens taken by TGW in our study resulted in 
greater than 20% reduction of both TFV and FTC taken as oral daily PrEP, possibly 
because of increases in renal clearance. The iFACT study made similar findings. We 
caution that the combination of a GAHT regimen and the on demand 2-1-1 PrEP regimen 
may result in TFV and FTC concentrations that fall below those associated with high 
levels of HIV protection. Conversely, neither our study nor the iFACT study 
demonstrated any effect of daily TDF/FTC on estrogen concentrations providing needed 
reassurance for TGW concerned that PrEP may negatively affect their GAHT regimen. 
More rigorous study designs are essential to explore the mechanism of the estrogen 
effect, better define the magnitude of related active TFV and FTC concentration changes 
in colorectal tissue, and confirm our dosing cautions with regard to GAHT and on 
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Figure 3.1. Concentration vs. time plots for TFV, FTC, TFV-DP, and FTC-TP on 
blood and colon tissue. 
 
 
Concentration vs. time plots for plasma tenofovir (TFV, Panel A) and emtricitabine 
(FTC, Panel B), and peripheral blood mononuclear cell (PBMC) TFV diphosphate (TFV-
DP, Panel C) and FTC triphosphate (FTC-TP, Panel D) comparing transgender women 
(TGW; dashed lines, squares) and cisgender men (CGM; solid lines, circles). Data are 
medians with error bars indicating lower and upper quartiles. Time values are slightly 






Figure 3.2. Kinase expression analyzed via immunoblotting for TFV-activating 
kinases in PBMC and colon tissue. 
 
Kinase expression analyzed via immunoblotting for tenofovir-activating kinases in 
peripheral blood mononuclear cells (PBMC) and colon tissue. PBMC and colon tissue 
were lysed and immunoblotting was performed using 50 µg of total protein lysate as 
described under Methods. Panel A. Immunoblotting of PBMC lysate for pyruvate kinase 
muscle (PKM), pyruvate kinase liver and red blood cell (PKLR), adenylate kinase 2 
(AK2), and glyceraldehyde 3-phosphatase dehydrogenase (GAPDH). Panel B. 
Immunoblotting of colon tissue lysate for creatine kinase muscle (CKM), adenylate 
kinase 2 (AK2), and β-actin. Participant identification numbers are indicated (1001, 1002, 

















Age, years 29 (26, 41) 46 (28, 52) 63 0.195‡ 
Weight, kg 98 (83, 123) 83 (71, 91) 118 0.130  
BMI 31 (24, 36) 23 (21, 27)  133 0.061 
Race, n (%)  
 
  
   Asian ancestry 1 (12) 0 (  0)  1.000§ 
   African ancestry 6 (75) 6 (75)   
   European ancestry 1 (12) 2 (25)   
†IQR, interquartile range 
‡Exact 2-sided p value, Wilcoxon rank sum test, comparing TGW and CGM 
§Fisher’s exact test 
 
 
Table 3.2. Hormone Regimens in TGW 
 
PID Estradiol (oral) Estradiol Valerate 
(IM) 
Premarin Spironolactone Medroxyprogesterone 
1010 
  
1.25 mg qd 
  
1011 6 mg q day 
  








0.5 mg q 2 weeks 
 
  50 mg q day 
 
1018 6 mg q day 20 mg q 2 weeks 
 
200 mg q day 
 




20 mg q 2 weeks 
 
100 mg q day 5 mg q day 
1021 
 
1.5 mg q 1 week 
 








Table 3.3. Tenofovir (TFV) pharmacokinetic parameters 
 







TFV Plasma ng/mL Cmax 301 (210, 392) 349 (269, 398) 86 0.721 
TFV Plasma ng/mL C24  41 (30, 52) 60 (55, 76) 68 0.010 
TFV Plasma ng-hr/mL AUC0-24 2,500 (1,712, 3,001) 3,431 (2,720, 3,649) 73 0.065 
TFV Plasma L/hr CLss/F 120 (100, 177) 87 (82, 110) 138 0.065 
TFV Plasma L Vz/F 2,110 (1,645, 3,391) 2,009 (1,442, 2,504) 105 0.574 
TFV-DP  PBMC fmol/106 cells Cmax 69 (51, 101) 83 (67, 118) 83 0.328 
TFV-DP  PBMC fmol/106 cells C24 51 (23, 97) 56 (34, 82) 90 0.982 
TFV-DP  PBMC fmol-hr/106 cells AUC0-24 1,239 (755, 1,560) 1,637 (1,404, 1,995) 76 0.121 
TFV  Colon homogenate ng/mg C24 0.48 (0.17, 0.54) 0.31 (0.16, 0.83) 153 0.977 
TFV-DP Colon homogenate fmol/mg C24 701 (368, 2,694) 1,329 (290, 4,231) 53 0.798 
TFV-DP Colon cells fmol/106 cells C24 1,238 (286, 4,811) 3,398 (881, 7,894) 36 0.442 
 
Abbreviations: TGW, transgender women; CGM, cisgender men; TFV-DP, TFV diphosphate; PBMC, peripheral blood mononuclear 
cells; Cmax, peak concentration; C24, trough concentration; AUC0-24, area under the concentration versus time curve from zero to 24 
hours; CLss/F, steady-state total clearance divided by bioavailability; Vz/F, volume of distribution based on the terminal phase   
†IQR is interquartile range 





Table 3.4. Emtricitabine (FTC) pharmacokinetic parameters 
 







FTC Plasma ng/mL Cmax 2,047 (1,442, 2,615) 2,284 (1,415, 2,889) 90 0.645 
FTC Plasma ng/mL C24  60 (51, 73) 88 (64, 102) 68 0.038 
FTC Plasma ng-hr/mL AUC0-24 9,682 (8,512, 10,926) 12,698 (11,114, 13,683) 76 0.028 
FTC Plasma L/hr CL/F 20.6 (18.3, 23.6) 15.8 (14.6, 18.0) 131 0.028 
FTC Plasma L Vz/F 187 (173, 230) 148 (140, 162) 126 0.065 
FTC-TP PBMC fmol/106 cells Cmax 10,617 (7,918, 12,880) 10,943 (8,702, 22,409) 97 0.382 
FTC-TP PBMC fmol/106 cells C24 5,110 (3,332, 10,255) 4,479 (2,659, 6,820) 114 0.645 
FTC-TP PBMC fmol-hr/106 cells AUC0-24 180,869 (122,399, 203,741) 204,467 (159,963, 272,918) 88 0.281 
FTC  Colon homogenate ng/mg C24 §BLQ (BLQ, 0.26) BLQ (BLQ, 0.25) - 0.706 
FTC-TP  Colon homogenate fmol/mg C24 123 (46, 183) 203 (84, 237) 60 0.279 
FTC-TP Colon cells fmol/106 cells C24 79 (BLQ¶, 297) 180 (121, 251) 44 0.393 
 
Abbreviations: TGW, transgender women; CGM, cisgender men; FTC-TP, FTC triphosphate; PBMC, peripheral blood 
mononuclear cells; Cmax, peak concentration; C24, trough concentration; AUC0-24, area under the concentration versus time 
curve from zero to 24 hours; CLss/F, steady-state total clearance divided by bioavailability; Vz/F, volume of distribution based 
on the terminal phase 
†IQR is interquartile range 
‡Exact 2-sided p value, Wilcoxon rank sum test, comparing transgender women (TGW) and cisgender men (CGM) 
§Values below the lower limit of assay quantitation (BLQ) are included in the median (IQR) estimates; 5 CGM and 4 TGW are 
BLQ for FTC colon homogenates. 




Table 3.5. Hormone Concentrations in transgender women (TGW) and cisgender men (CGM). Data other than p 
values are median (interquartile range).  
 
Hormone TGW Day 0 
 
TGW Day 7 CGM Day 7 Pre vs. Post TDF/FTC 
p value† 
TGW vs. CGM 
p value† 
Estradiol (pg/mL) 221 (60, 615) 380 (208, 437) 15 (12, 23) 0.669 <0.001 
FSH (mIU/mL) 0.17 (0.10, 3.23) 0.10 (0.10, 3.87) 4.02 (2.23, 5.83) 0.806 0.047 
LH (mIU/mL) 0.88 (0.13, 4.16) 0.46 (0.16, 5.63) 5.45 (2.98, 7.62) 0.626 0.048 
Total Testosterone (ng/dL) 15 (10, 90) 17 (10, 297) 422 (346, 605) 0.151 0.028 
Free Testosterone (ng/dL) 0.34 (0.19, 2.03) 0.35 (0.30, 3.48) 12.65 (8.10, 17.70) 0.375 0.011 
 
†Exact 2-sided p value, Wilcoxon rank sum test, comparing pre-TDF/FTC dosing (Day 0) to post-TDF/FTC dosing (Day 7) or 
comparing TGW to CGM 
‡All TGW had estradiol concentrations greater than 100 pg/ML per protocol at screening. One subject fell below this value on 





Table 3.6. Estimated creatinine clearance (CrCl) and estimated glomerular filtration rate (eGFR) on study day 7. 
 







 Serum Creatinine (mg/dL) 0.80 (0.80, 0.88) 1.05 (1.00, 1.18) 76 0.002 
 CrCl Cockcroft-Gault (mL/min) 204 (120, 218) 108 (83, 125) 188 0.008 
 eGFR MDRD (mL/min/1.73m2)  130 (117, 142) 89 (79, 98) 146 0.002 
 eGFR CKD-EPI (mL/min/1.73m2) 133 (124, 142) 114 (109, 118) 116 0.003 
 §CrCl Cockcroft-Gault  [TGW=F] (mL/min)  174 (102, 185) 109 (83, 125) 160 0.035 
 §eGFR MDRD [TGW=F] (mL/min/1.73m2) 97 (86, 105) 89 (79, 98) 109 0.442 
 §eGFR CKD-EPI [TGW=F] 
(mL/min/1.73m2) 
107 (100, 118) 98 (81, 106) 109 0.315 
 
Abbreviations: TGW, transgender women; CGM, cisgender men; MDRD, Modification of Diet in Renal Disease Study 
equation;  
CKDEPI, Chronic Kidney Disease Epidemiology Collaboration equation 
†IQR – interquartile range (lower quartile, upper quartile) 
‡Exact 2-sided p value, Wilcoxon rank sum test, comparing TGW and CGM 





CHAPTER 4: Conclusion 
 
The vulnerability of oral and vaginal PrEP efficacy to adherence points to the need to 
improve current PrEP options and develop alternate formulations. Regardless of 
formulation, a successful PrEP strategy has to take into account the lifestyle, concerns 
and personal preferences of its users. The failure of vaginal PrEP showing no efficacy in 
women [12, 20] has made it clear that HIV PrEP cannot succeed without user buy-in and 
without taking lifestyle and preferences into account. Furthermore, the poor adherence of 
oral daily PrEP in TGW leading to no efficacy in subgroup analyses suggest that PrEP 
will not succeed if merely adapted from MSM to TGW [16]. TGW are a unique 
population with different social, biological, psychological and lifestyle needs that impact 
their views, uptake and use of HIV PrEP.  
 
With the varying needs of individuals in mind, this thesis embraces a user-centric 
approach to the clinical pharmacology of HIV prevention in MSM and TGW with a 
broader view that this strategy will improve uptake and adherence. Chapter 2 addresses 
the feasibility of developing a medicated lubricant for HIV prevention, which is desired 
by many MSM, while Chapter 3 addresses a specific high level concern of TGW that 
HIV PrEP will adversely impact their gender-affirming hormonal treatment.  
 
Chapter 2 asks the question of whether using a medicated lube in the same manner as a 
sexual lubricant can achieve adequate colorectal distribution for rectal HIV prevention. 
The study found that dosing a rectal microbicide gel in the typical way a sexual lubricant 




rectosigmoid distribution compared to applicator dosing. Designed for immediate use 
prior to potential rectal HIV-1 exposure, rectal microbicide products should rapidly 
achieve and sustain a targeted surface area in the colon. This study suggests that manual 
dosing with rectal microbicide formulations currently in development may not reliably 
provide sufficient drug delivery to the area of likely HIV infection needed for HIV 
prevention.  
 
Chapter 3 is a pharmacokinetic (PK) study examining the two-way drug-drug interaction 
of oral TFV-FTC and GAHT in TGW.  Chapter 3 provides pharmacokinetic evidence 
that daily oral PrEP with TDF/FTC has no impact on GAHT in TGW, consistent with 
another study conducted in parallel. Surprisingly, the study suggests that GAHT modestly 
reduces TFV and FTC plasma concentrations though not to a degree that likely impacts 
the efficacy of daily oral PrEP in HIV prevention. While the concentration decrease in 
TFV and FTC in TGW on GAHT was modest, it suggests that adherence to daily oral 
PrEP is even more critical, as missing doses or using PrEP on demand while on GAHT 
may not provide drug concentrations sufficient for HIV prevention. Because of the 
modest concentration decrease, increasingly popular on demand 2+1+1 regimens, such as 
those studied in Ipergay and Prevenir, may not provide high levels of HIV protection. 
 
4.1 Future Directions 
MSM desire a rectal microbicide gel that fits seamlessly with their lifestyle. Chapter 2 
raises concerns that applying lubricant gel in this manner, or manual dosing, may need 




prevention. The findings in Chapter 2, however, are based solely on imaging studies. A 
larger study MTN-033/IPM-044 is currently in progress to compare the effect of manual 
and applicator dosing of dapivirine rectal gel on tissue concentration and ex vivo HIV 
efficacy. In combination with the results of Chapter 2, the results of MTN-033/IPM-044 
will inform the feasibility of manual dosing of a current rectal microbicide formulation in 
development. Should this study show that manual dosing does not achieve HIV-
protective tissue concentrations, future studies should look into increasing the 
concentration of antiviral drug in the rectal formulation to achieve HIV-protective tissue 
concentrations and adequate colorectal distribution with manual dosing (as lubricant). 
Without manual dosing, product acceptance and adherence of rectal microbicide gel for 
use in RAI may be challenging. Several anal douche formulations – incorporating either 
tenofovir or griffithsin - are also in development as behaviorally-congruent, on demand 
rectal microbicide strategies.  
 
Whereas MSM-directed HIV PrEP research is bountiful in MSM, there has been a dearth 
of TGW-focused HIV PrEP research, a gap that TGW cite as a barrier to PrEP uptake and 
use. Chapter 3 not only provides much-needed TGW-focused PrEP research, but also 
reassuring pharmacokinetic evidence for TGW on GAHT that daily oral PrEP does not 
adversely affect their GAHT. In addition, daily oral TDF/FTC forPrEP likely provides 
concentrations sufficient to protect against HIV. The decreased TFV and FTC 
concentrations seen in TGW also on GAHT seen in this study, as well as the Thai Red 
Cross/HIVNAT iFACT study [70], while modest, should be assessed further to determine 




2+1+1 oral PrEP regimens may not provide sufficient HIV-concentrations in TGW on 
GAHT and as the burden of a daily dosing regimen may not be acceptable to all 
individuals, alternate formulations should be explored in TGW on GAHT. 
  
4.2 Conclusion 
Drug development in HIV prevention cannot occur in isolation and must value the end-
user’s preferences and lifestyle. Without taking account of varied preferences and 
lifestyles of individuals at risk of HIV infection, HIV PrEP development has shown that 
HIV prevention product development may not succeed. Altogether, this thesis takes a 
step toward developing a medicated lubricant for MSM and provides TGW-focused 
research that takes into account GAHT use. By considering the end user’s preferences, 
concerns and lifestyle, the studies in this thesis utilize a user-centric approach to 
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